United Therapeutics Corp. SEC Filings

UNITED THERAPEUTICS (UTHR) filed a Form 144 disclosing a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,778,788.40, slated for 10/10/2025 on NASDAQ. The filing shows the shares were originally acquired on 03/15/2016 as executive deferred compensation from Martine Rothblatt, with 294,000 shares acquired in that transaction and payment made via vested options exercised with common shares. The notice also lists multiple recent sales by the same person totaling 88,000 shares sold across dates from 09/09/2025 to 10/09/2025, with individual daily proceeds ranging roughly from $1.59M to $1.81M. The filer certifies no undisclosed material adverse information and includes standard Rule 10b5-1 language where applicable.

United Therapeutics (UTHR) insider sale notice: An officer/director-level holder filed a Form 144 to sell 4,000 common shares with an aggregate market value of $1,795,655.20 planned on 10/09/2025 through TD Securities (USA) LLC on the NASDAQ. The filing shows these shares were originally acquired on 03/15/2016 via executive deferred compensation from Martine Rothblatt and were exercised via vested options with payment made in common shares. The filing also lists multiple recent disposals of common shares by Martine Rothblatt on dates across 09/09/2025 to 10/08/2025, each transaction showing 4,000 shares on most dates and one 8,000-share sale on 09/09/2025, with individual gross proceeds reported per trade. The filer certifies no undisclosed material adverse information and includes routine signature/attestation language.

United Therapeutics (UTHR) Form 144 shows a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,803,449.20 and an approximate sale date of 10/08/2025. The filing reports the shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement and notes 294,000 shares were acquired at that time via exercised options paid with common shares.

The notice lists numerous sales by Martine Rothblatt during 09/09/2025–10/07/2025, typically in blocks of 4,000 shares per transaction, with gross proceeds shown for each date. The filing states the seller represents no undisclosed material adverse information about the issuer.

United Therapeutics director and CEO Martine A. Rothblatt executed and sold stock under a pre-arranged 10b5-1 trading plan entered 05/02/2025. On 10/07/2025 and 10/08/2025 she exercised a total of 8,000 stock options with an exercise price of $120.26 per share, converting those options into 8,000 common shares. Simultaneously, the reporting person sold a total of 8,000 common shares in multiple transactions at weighted-average prices in the mid-$440s to mid-$450s, with reported weighted averages and price ranges disclosed for the trades. Following these transactions, the reporting person reports 202,000 options remaining exercisable and various indirect holdings: 324,518, 258,117, 45,596, and 15,962 shares held in family trusts and 166 shares held indirectly by spouse. The Form 4 states the 10b5-1 plan will continue until the earlier of exhaustion of a tranche of 294,000 stock options expiring 03/15/2026 or 12/31/2025.

Insider exercise and sales under a 10b5-1 plan on 10/06/2025

The President and COO of United Therapeutics (UTHR) exercised a total of 22,500 stock options on 10/06/2025 (14,625 options at a $135.42 strike; 7,875 at $146.03) and immediately sold many of the resulting shares from trusts for which he has shared or sole trustee powers. Multiple sales were executed in tranches with weighted‑average prices reported in the range of approximately $449.45 to $454.81, with specific weighted averages shown (for example, $449.82, $450.97, $452.03, $453.16, $253.975). Transactions were made pursuant to a Rule 10b5‑1 trading plan established on 06/03/2025. Following the reported transactions, the reporting person beneficially owned optioned shares and remaining common stock indirectly through trusts, with listed post‑transaction holdings such as 14,325 and 7,875 underlying shares shown for the respective option series.

UNITED THERAPEUTICS (UTHR) reported a Rule 144 notice disclosing a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,807,320. The filing shows these shares were acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, and payment was made by exercising vested options with shares used for payment. The issuer has 45,230,000 shares outstanding, so the single proposed block equals roughly 0.009% of outstanding stock. The filing also itemizes prior open-market sales by the same person totaling 80,000 shares over the past three months, generating multi‑million dollar proceeds on multiple dates.

United Therapeutics director and Chairperson & CEO Martine A. Rothblatt reported option exercises and subsequent sales under a pre-arranged 10b5-1 trading plan entered on 05/02/2025. On 10/03/2025 and 10/06/2025 she exercised a total of 8,000 stock options with a $120.26 exercise price and sold multiple blocks of shares at weighted-average prices ranging roughly from $445 to $451. Following the reported transactions she directly beneficially owned 4,130 shares and indirectly held large positions through family trusts and spouse (e.g., 324,518, 258,117, 45,596, 15,962). The 10b5-1 plan covers a tranche of 294,000 options expiring 03/15/2026 or ending by 12/31/2025, whichever is earlier. The filing states multiple trades were executed at specified price ranges and offers to provide transaction details on request.

United Therapeutics (UTHR) insider sale notice: An officer/director filed a Form 144 proposing the sale of 4,000 common shares through TD Securities (USA) LLC on 10/06/2025

The filing shows an aggregate market value of $1,798,765.20 for the 4,000 shares and reports the original acquisition on 03/15/2016 via executive deferred compensation consisting of 294,000 shares from Martine Rothblatt. The notice also lists multiple recent open-market sales by the same person between 09/09/2025 and 10/03/2025, with per-day sale quantities of 4,000 shares (one 8,000-share sale on 09/09/2025) and gross proceeds shown for each date. The filer certifies no undisclosed material information and identifies broker details and share counts but does not state total outstanding shares beyond the single row count of 45,230,000.

United Therapeutics (UTHR) filed a Form 144 reporting a proposed sale of 90,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on 10/06/2025 on NASDAQ. The shares were acquired and paid for on 10/06/2025 through an exercise of stock options and funded in cash. The filing lists the aggregate market value of the shares as $40,776,300.00 and total shares outstanding as 45,226,262.

The notice also discloses multiple Rule 10b5-1 sales attributed to Michael Benkowitz during September 2025 totaling several transactions (examples: 7,875 and 14,625 share blocks) with gross proceeds reported per trade. The filer affirms no undisclosed material nonpublic information and includes the standard signature/attestation language required by the form.